Atlatsa Announces A Further Annual General Meeting Date Extension
JOHANNESBURG, Sept. 21, 2018 /CNW/ - Atlatsa Resources Corporation (the "Company") (TSX: ATL; JSE: ATL) advises that it has obtained consent from the Toronto Stock Exchange and the British Columbia Registry Services for a further extension of the outside date for its annual general meeting of shareholders, which meeting is now to be held by no later than December 31, 2018 (the "Outside Date").
The Company is actively engaged in finalizing the terms of Phase 2 of its previously announced 2017 Restructure Plan with Anglo American Platinum Limited (please refer to the announcement published by the Company on July 21, 2017 for further information on Phase 2 of the 2017 Restructure Plan). The 2017 Restructure Plan, which remains subject to, inter alia, finalization and execution of definitive transaction agreements and receipt of all corporate and regulatory approvals, is expected to be presented to Atlatsa shareholders for approval at an annual general and special meeting of the Company to take place by no later than the Outside Date.
Rakovina Therapeutics Inc. a biopharmaceutical company committed to advancing new cancer therapies based on novel DNA-damage response technologies announced the financial results for its fourth quarter and fiscal year ending December 31, 2023 and...
Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New...
Regenx Tech Corp., (the "Company" or "Regenx") is providing this bi-weekly update on the status of the application to the Alberta Securities Commission for a management cease trade order, under National Policy 12-203 -?? Management Cease Trade...
Kadestone Capital Corp. ("Kadestone" or the "Company") , a vertically integrated property company today announced its financial results for the year ended December 31, 2023....
Appili Therapeutics Inc. (the "Company" or "Appili"), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, today announced it has secured additional bridge financing in the amount of C$300,000...
